1
|
Cuceu C, Colicchio B, Jeandidier E, Junker S, Plassa F, Shim G, Mika J, Frenzel M, Al Jawhari M, Hempel WM, Kabacik S, Lenain A, Morat L, Girinsky T, Dieterlen A, Polanska J, Badie C, Carde P, M'Kacher R. Erratum: Cuceu, C., et al. Independent Mechanisms Lead to Genomic Instability in Hodgkin Lymphoma: Microsatellite or Chromosomal Instability. Cancers 2018, 10, 233. Cancers (Basel) 2019; 11:cancers11060757. [PMID: 31151278 PMCID: PMC6627774 DOI: 10.3390/cancers11060757] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2019] [Accepted: 05/09/2019] [Indexed: 12/14/2022] Open
Affiliation(s)
- Corina Cuceu
- Radiobiology and Oncology Laboratory, CEA, iRCM, 92265 Fontenay aux Roses CEDEX, France.
| | - Bruno Colicchio
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, 68093 Mulhouse, France.
| | - Eric Jeandidier
- Department of Genetic, Groupe Hospitalier de la Région de Mulhouse Sud-Alsace, 68093 Mulhouse, France.
| | - Steffen Junker
- Institute of Biomedicine, University of Aarhus, DK-8000 Aarhus, Denmark.
| | - François Plassa
- Laboratory of Biochemistry B, Saint Louis Hospital, 75010 Paris, France.
| | - Grace Shim
- Radiobiology and Oncology Laboratory, CEA, iRCM, 92265 Fontenay aux Roses CEDEX, France.
| | - Justyna Mika
- Faculty of Automatic Control, Electronics and Computer Science, Silesian University of Techology, 44-100 Gliwice, Poland.
| | - Monika Frenzel
- Radiobiology and Oncology Laboratory, CEA, iRCM, 92265 Fontenay aux Roses CEDEX, France.
| | - Mustafa Al Jawhari
- Radiobiology and Oncology Laboratory, CEA, iRCM, 92265 Fontenay aux Roses CEDEX, France.
| | - William M Hempel
- Radiobiology and Oncology Laboratory, CEA, iRCM, 92265 Fontenay aux Roses CEDEX, France.
| | - Sylwia Kabacik
- Biological Effects Department, Centre for Radiation, Chemical and Environmental Hazards, Public Health England, Didcot OX11 ORQ, UK.
| | - Aude Lenain
- Radiobiology and Oncology Laboratory, CEA, iRCM, 92265 Fontenay aux Roses CEDEX, France.
| | - Luc Morat
- Radiobiology and Oncology Laboratory, CEA, iRCM, 92265 Fontenay aux Roses CEDEX, France.
| | - Theodore Girinsky
- Department of Radiation Oncology, Gustave Roussy Cancer Campus, 94805 Villejuif, France.
| | - Alain Dieterlen
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, 68093 Mulhouse, France.
| | - Joanna Polanska
- Faculty of Automatic Control, Electronics and Computer Science, Silesian University of Techology, 44-100 Gliwice, Poland.
| | - Christophe Badie
- Biological Effects Department, Centre for Radiation, Chemical and Environmental Hazards, Public Health England, Didcot OX11 ORQ, UK.
| | - Patrice Carde
- Department of Medicine, Gustave Roussy Cancer Campus, University Paris Saclay, 94805 Villejuif, France.
| | - Radhia M'Kacher
- Radiobiology and Oncology Laboratory, CEA, iRCM, 92265 Fontenay aux Roses CEDEX, France.
- Cell Environment DNA Damages R&D Oncology Section, 75020 Paris, France.
| |
Collapse
|
2
|
M'kacher R, Frenzel M, Al Jawhari M, Junker S, Cuceu C, Morat L, Bauchet AL, Stimmer L, Lenain A, Dechamps N, Hempel WM, Pottier G, Heidingsfelder L, Laplagne E, Borie C, Oudrhiri N, Jouni D, Bennaceur-Griscelli A, Colicchio B, Dieterlen A, Girinsky T, Boisgard R, Bourhis J, Bosq J, Mehrling T, Jeandidier E, Carde P. Establishment and Characterization of a Reliable Xenograft Model of Hodgkin Lymphoma Suitable for the Study of Tumor Origin and the Design of New Therapies. Cancers (Basel) 2018; 10:cancers10110414. [PMID: 30384446 PMCID: PMC6265845 DOI: 10.3390/cancers10110414] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2018] [Revised: 10/25/2018] [Accepted: 10/26/2018] [Indexed: 01/16/2023] Open
Abstract
To identify the cells responsible for the initiation and maintenance of Hodgkin lymphoma (HL) cells, we have characterized a subpopulation of HL cells grown in vitro and in vivo with the aim of establishing a reliable and robust animal model for HL. To validate our model, we challenged the tumor cells in vivo by injecting the alkylating histone-deacetylase inhibitor, EDO-S101, a salvage regimen for HL patients, into xenografted mice. Methodology: Blood lymphocytes from 50 HL patients and seven HL cell lines were used. Immunohistochemistry, flow cytometry, and cytogenetics analyses were performed. The in vitro and in vivo effects of EDO-S101 were assessed. Results: We have successfully determined conditions for in vitro amplification and characterization of the HL L428-c subline, containing a higher proportion of CD30−/CD15− cells than the parental L428 cell line. This subline displayed excellent clonogenic potential and reliable reproducibility upon xenografting into immunodeficient NOD-SCID-gamma (−/−)(NSG) mice. Using cell sorting, we demonstrate that CD30−/CD15− subpopulations can gain the phenotype of the L428-c cell line in vitro. Moreover, the human cells recovered from the seventh week after injection of L428-c cells into NSG mice were small cells characterized by a high frequency of CD30−/CD15− cells. Cytogenetic analysis demonstrated that they were diploid and showed high telomere instability and telomerase activity. Accordingly, chromosomal instability emerged, as shown by the formation of dicentric chromosomes, ring chromosomes, and breakage/fusion/bridge cycles. Similarly, high telomerase activity and telomere instability were detected in circulating lymphocytes from HL patients. The beneficial effect of the histone-deacetylase inhibitor EDO-S101 as an anti-tumor drug validated our animal model. Conclusion: Our HL animal model requires only 103 cells and is characterized by a high survival/toxicity ratio and high reproducibility. Moreover, the cells that engraft in mice are characterized by a high frequency of small CD30−/CD15− cells exhibiting high telomerase activity and telomere dysfunction.
Collapse
Affiliation(s)
- Radhia M'kacher
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
- Cell Environment, Oncology Section, 75020 Paris, France.
| | - Monika Frenzel
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
| | - Mustafa Al Jawhari
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
| | - Steffen Junker
- Institute of Biomedicine, University of Aarhus, DK-8000 Aarhus C, Denmark.
| | - Corina Cuceu
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
| | - Luc Morat
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
| | - Anne-Laure Bauchet
- Platform for Experimental Pathology PathEX/CRC MIRCen/CEA-INSERM, University Paris-Saclay, 92265 Fontenay aux Rroses, France.
| | - Lev Stimmer
- Platform for Experimental Pathology PathEX/CRC MIRCen/CEA-INSERM, University Paris-Saclay, 92265 Fontenay aux Rroses, France.
| | - Aude Lenain
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
| | - Nathalie Dechamps
- Platform for Cell Sorting, CEA, iRCM, 92265 Fontenay aux Roses, France.
| | - William M Hempel
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
| | - Geraldine Pottier
- Laboratoire d'Imagerie Moléculaire Expérimentale Groupe d'Imagerie du Petit Animal CEA/DSV/I2BM/SHFJ/U1023, University Paris-Saclay, 91400 Orsay, France.
| | | | | | - Claire Borie
- APHP-Hopital Paul Brousse Université Paris Sud/ESteam Paris Inserm UMR 935, 94800 Villejuif, France.
| | - Noufissa Oudrhiri
- APHP-Hopital Paul Brousse Université Paris Sud/ESteam Paris Inserm UMR 935, 94800 Villejuif, France.
| | - Dima Jouni
- APHP-Hopital Paul Brousse Université Paris Sud/ESteam Paris Inserm UMR 935, 94800 Villejuif, France.
| | | | - Bruno Colicchio
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, 68093 Mulhouse, France.
| | - Alain Dieterlen
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, 68093 Mulhouse, France.
| | - Theodore Girinsky
- Department of Radiation Oncology, Gustave Roussy Cancer Campus, University Paris-Saclay, 94805 Villejuif, France.
| | - Raphael Boisgard
- Laboratoire d'Imagerie Moléculaire Expérimentale Groupe d'Imagerie du Petit Animal CEA/DSV/I2BM/SHFJ/U1023, University Paris-Saclay, 91400 Orsay, France.
| | - Jean Bourhis
- Department of Radiation Oncology, Gustave Roussy Cancer Campus, University Paris-Saclay, 94805 Villejuif, France.
| | - Jacques Bosq
- Departement of Anapathology, Gustave Roussy Cancer Campus, University Paris-Saclay, 94805 Vilejuif, France.
| | | | - Eric Jeandidier
- Department of Genetic, Groupe Hospitalier de la Région de Mulhouse Sud-Alsace, 68093 Mulhouse, France.
| | - Patrice Carde
- Department of Medicine, Gustave Roussy Cancer Campus, University Paris-Saclay, 94805 Villejuif, France.
| |
Collapse
|
3
|
M'kacher R, Cuceu C, Al Jawhari M, Morat L, Frenzel M, Shim G, Lenain A, Hempel WM, Junker S, Girinsky T, Colicchio B, Dieterlen A, Heidingsfelder L, Borie C, Oudrhiri N, Bennaceur-Griscelli A, Moralès O, Renaud S, Van de Wyngaert Z, Jeandidier E, Delhem N, Carde P. The Transition between Telomerase and ALT Mechanisms in Hodgkin Lymphoma and Its Predictive Value in Clinical Outcomes. Cancers (Basel) 2018; 10:E169. [PMID: 29848986 PMCID: PMC6025489 DOI: 10.3390/cancers10060169] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2018] [Revised: 05/18/2018] [Accepted: 05/25/2018] [Indexed: 11/16/2022] Open
Abstract
Background: We analyzed telomere maintenance mechanisms (TMMs) in lymph node samples from HL patients treated with standard therapy. The TMMs correlated with clinical outcomes of patients. Materials and Methods: Lymph node biopsies obtained from 38 HL patients and 24 patients with lymphadenitis were included in this study. Seven HL cell lines were used as in vitro models. Telomerase activity (TA) was assessed by TRAP assay and verified through hTERT immunofluorescence expression; alternative telomere lengthening (ALT) was also assessed, along with EBV status. Results: Both TA and ALT mechanisms were present in HL lymph nodes. Our findings were reproduced in HL cell lines. The highest levels of TA were expressed in CD30-/CD15- cells. Small cells were identified with ALT and TA. Hodgkin and Reed Sternberg cells contained high levels of PML bodies, but had very low hTERT expression. There was a significant correlation between overall survival (p < 10-3), event-free survival (p < 10-4), and freedom from progression (p < 10-3) and the presence of an ALT profile in lymph nodes of EBV+ patients. Conclusion: The presence of both types of TMMs in HL lymph nodes and in HL cell lines has not previously been reported. TMMs correlate with the treatment outcome of EBV+ HL patients.
Collapse
Affiliation(s)
- Radhia M'kacher
- Laboratoire de Radiobiologie et d'Oncologie, IRCM/DSV/CEA, 92265 Fontenay aux Roses, France.
- Cell Environment, DNA Damages R&D, Oncology Section, 75020 Paris, France.
| | - Corina Cuceu
- Laboratoire de Radiobiologie et d'Oncologie, IRCM/DSV/CEA, 92265 Fontenay aux Roses, France.
| | - Mustafa Al Jawhari
- Laboratoire de Radiobiologie et d'Oncologie, IRCM/DSV/CEA, 92265 Fontenay aux Roses, France.
| | - Luc Morat
- Laboratoire de Radiobiologie et d'Oncologie, IRCM/DSV/CEA, 92265 Fontenay aux Roses, France.
| | - Monika Frenzel
- Laboratoire de Radiobiologie et d'Oncologie, IRCM/DSV/CEA, 92265 Fontenay aux Roses, France.
| | - Grace Shim
- Laboratoire de Radiobiologie et d'Oncologie, IRCM/DSV/CEA, 92265 Fontenay aux Roses, France.
| | - Aude Lenain
- Laboratoire de Radiobiologie et d'Oncologie, IRCM/DSV/CEA, 92265 Fontenay aux Roses, France.
| | - William M Hempel
- Laboratoire de Radiobiologie et d'Oncologie, IRCM/DSV/CEA, 92265 Fontenay aux Roses, France.
| | - Steffen Junker
- Institute of Biomedicine, University of Aarhus, DK-8000 Aarhus C, Denmark.
| | - Theodore Girinsky
- Department of Radiation Therapy, Gustave Roussy Cancer Campus, 94808 Villejuif, France.
| | - Bruno Colicchio
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, 68093 Mulhouse, France.
| | - Alain Dieterlen
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, 68093 Mulhouse, France.
| | | | - Claire Borie
- Université Paris Sud, Service d'hématologie moléculaire et cytogénétique Paul brousse CHU paris Sud, Inserm UMRS935, 94800 Villejuif, France.
| | - Noufissa Oudrhiri
- Université Paris Sud, Service d'hématologie moléculaire et cytogénétique Paul brousse CHU paris Sud, Inserm UMRS935, 94800 Villejuif, France.
| | - Annelise Bennaceur-Griscelli
- Université Paris Sud, Service d'hématologie moléculaire et cytogénétique Paul brousse CHU paris Sud, Inserm UMRS935, 94800 Villejuif, France.
| | - Olivier Moralès
- CNRS, Institut Pasteur de Lille, UMR 8161-Immunoregulation of Virus-induced Cancers Team, F-59000 Lille, France.
| | - Sarah Renaud
- CNRS, Institut Pasteur de Lille, UMR 8161-Immunoregulation of Virus-induced Cancers Team, F-59000 Lille, France.
| | - Zoé Van de Wyngaert
- CHRU Lille Service des Maladies du Sang, Hopital Huriez, 59000 Lille, France.
| | - Eric Jeandidier
- Service de génétique, Groupe hospitalier de la région de Mulhouse Sud-Alsace, 68093 Mulhouse, France.
| | - Nadira Delhem
- CNRS, Institut Pasteur de Lille, UMR 8161-Immunoregulation of Virus-induced Cancers Team, F-59000 Lille, France.
| | - Patrice Carde
- Department of Medicine, Gustave Roussy Cancer Campus, 94808 Villejuif, France.
| |
Collapse
|
4
|
Kaddour A, Colicchio B, Buron D, El Maalouf E, Laplagne E, Borie C, Ricoul M, Lenain A, Hempel WM, Morat L, Al Jawhari M, Cuceu C, Heidingsfelder L, Jeandidier E, Deschênes G, Dieterlen A, El May M, Girinsky T, Bennaceur-Griscelli A, Carde P, Sabatier L, M'kacher R. Transmission of Induced Chromosomal Aberrations through Successive Mitotic Divisions in Human Lymphocytes after In Vitro and In Vivo Radiation. Sci Rep 2017; 7:3291. [PMID: 28607452 PMCID: PMC5468351 DOI: 10.1038/s41598-017-03198-7] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2017] [Accepted: 04/24/2017] [Indexed: 11/10/2022] Open
Abstract
The mechanisms behind the transmission of chromosomal aberrations (CA) remain unclear, despite a large body of work and major technological advances in chromosome identification. We reevaluated the transmission of CA to second- and third-division cells by telomere and centromere (TC) staining followed by M-FISH. We scored CA in lymphocytes of healthy donors after in vitro irradiation and those of cancer patients treated by radiation therapy more than 12 years before. Our data demonstrate, for the first time, that dicentric chromosomes (DCs) decreased by approximately 50% per division. DCs with two centromeres in close proximity were more efficiently transmitted, representing 70% of persistent DCs in ≥M3 cells. Only 1/3 of acentric chromosomes (ACs), ACs with four telomeres, and interstitial ACs, were paired in M2 cells and associated with specific DCs configurations. In lymphocytes of cancer patients, 82% of detected DCs were characterized by these specific configurations. Our findings demonstrate the high stability of DCs with two centromeres in close proximity during cell division. The frequency of telomere deletion increased during cell cycle progression playing an important role in chromosomal instability. These findings could be exploited in the follow-up of exposed populations.
Collapse
Affiliation(s)
- Akram Kaddour
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, Paris-Saclay, France.,Tunis El Manar University, School of Medicine, Tunis, Tunisia
| | - Bruno Colicchio
- Laboratoire MIPS Groupe IMTI Université de Haute-Alsace, Mulhouse, France
| | - Diane Buron
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, Paris-Saclay, France
| | - Elie El Maalouf
- Laboratoire MIPS Groupe IMTI Université de Haute-Alsace, Mulhouse, France
| | | | - Claire Borie
- APHP-Hopital Paul Brousse Université Paris Sud/ESteam Paris Inserm UMR 935, Villejuif, France
| | - Michelle Ricoul
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, Paris-Saclay, France
| | - Aude Lenain
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, Paris-Saclay, France
| | - William M Hempel
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, Paris-Saclay, France
| | - Luc Morat
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, Paris-Saclay, France
| | - Mustafa Al Jawhari
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, Paris-Saclay, France
| | - Corina Cuceu
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, Paris-Saclay, France
| | | | - Eric Jeandidier
- Service de Génétique Groupe Hospitalier de la Région de Mulhouse et Sud Alsace, 68070, Mulhouse, France
| | | | - Alain Dieterlen
- Laboratoire MIPS Groupe IMTI Université de Haute-Alsace, Mulhouse, France
| | - Michèle El May
- Tunis El Manar University, School of Medicine, Tunis, Tunisia
| | - Theodore Girinsky
- Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France
| | | | - Patrice Carde
- Department of Hematology, Gustave Roussy cancer Campus, Villejuif, France
| | - Laure Sabatier
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, Paris-Saclay, France
| | - Radhia M'kacher
- Laboratory of Radiobiology and Oncology and PROCyTOX, DRF, CEA, Paris-Saclay, France. .,Cell Environment, Paris, France.
| |
Collapse
|
5
|
Finot F, Kaddour A, Morat L, Mouche I, Zaguia N, Cuceu C, Souverville D, Négrault S, Cariou O, Essahli A, Prigent N, Saul J, Paillard F, Heidingsfelder L, Lafouge P, Al Jawhari M, Hempel WM, El May M, Colicchio B, Dieterlen A, Jeandidier E, Sabatier L, Clements J, M'Kacher R. Cover image. J Appl Toxicol 2017. [DOI: 10.1002/jat.3486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
6
|
Finot F, Kaddour A, Morat L, Mouche I, Zaguia N, Cuceu C, Souverville D, Négrault S, Cariou O, Essahli A, Prigent N, Saul J, Paillard F, Heidingsfelder L, Lafouge P, Al Jawhari M, Hempel WM, El May M, Colicchio B, Dieterlen A, Jeandidier E, Sabatier L, Clements J, M'Kacher R. Genotoxic risk of ethyl-paraben could be related to telomere shortening. J Appl Toxicol 2016; 37:758-771. [DOI: 10.1002/jat.3425] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2016] [Revised: 11/01/2016] [Accepted: 11/01/2016] [Indexed: 01/22/2023]
Affiliation(s)
- F. Finot
- Covance Laboratory; 78440 Porcheville France
- Cell Environment; Paris France
| | - A. Kaddour
- Cell Environment; Paris France
- Tunis El Manar University; School of Medicine; Tunis Tunisia
| | - L. Morat
- Radiology and Oncology Laboratory, IRCM, DSV; Commissariat à l'energie atomique (CEA); Fontenay-aux Roses France
| | - I. Mouche
- Covance Laboratory; 78440 Porcheville France
- Cell Environment; Paris France
| | - N. Zaguia
- Radiology and Oncology Laboratory, IRCM, DSV; Commissariat à l'energie atomique (CEA); Fontenay-aux Roses France
| | - C. Cuceu
- Radiology and Oncology Laboratory, IRCM, DSV; Commissariat à l'energie atomique (CEA); Fontenay-aux Roses France
| | | | - S. Négrault
- Covance Laboratory; 78440 Porcheville France
| | - O. Cariou
- Covance Laboratory; 78440 Porcheville France
| | - A. Essahli
- Covance Laboratory; 78440 Porcheville France
| | - N. Prigent
- Covance Laboratory; 78440 Porcheville France
| | - J. Saul
- Covance Laboratories; Yorkshire HG3 1PY UK
| | - F. Paillard
- Covance Laboratory; 78440 Porcheville France
| | | | - P. Lafouge
- Covance Laboratory; 78440 Porcheville France
| | | | - W. M. Hempel
- Radiology and Oncology Laboratory, IRCM, DSV; Commissariat à l'energie atomique (CEA); Fontenay-aux Roses France
| | - M. El May
- Tunis El Manar University; School of Medicine; Tunis Tunisia
| | - B. Colicchio
- Laboratoire MIPS - Groupe IMTI Université de Haute-Alsace; F-68093 Mulhouse France
| | - A. Dieterlen
- Laboratoire MIPS - Groupe IMTI Université de Haute-Alsace; F-68093 Mulhouse France
| | - E. Jeandidier
- Service de génétique Groupe Hospitalier de la Région de Mulhouse et Sud Alsace; 68070 Mulhouse France
| | - L. Sabatier
- Radiology and Oncology Laboratory, IRCM, DSV; Commissariat à l'energie atomique (CEA); Fontenay-aux Roses France
| | | | - R. M'Kacher
- Cell Environment; Paris France
- Radiology and Oncology Laboratory, IRCM, DSV; Commissariat à l'energie atomique (CEA); Fontenay-aux Roses France
| |
Collapse
|
7
|
Viau M, Testard I, Shim G, Morat L, Normil MD, Hempel WM, Sabatier L. Global quantification of γH2AX as a triage tool for the rapid estimation of received dose in the event of accidental radiation exposure. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 2015; 793:123-31. [DOI: 10.1016/j.mrgentox.2015.05.009] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/24/2015] [Accepted: 05/26/2015] [Indexed: 10/23/2022]
|
8
|
M'kacher R, Girinsky T, Colicchio B, Ricoul M, Dieterlen A, Jeandidier E, Heidingsfelder L, Cuceu C, Shim G, Frenzel M, Lenain A, Morat L, Bourhis J, Hempel WM, Koscielny S, Paul JF, Carde P, Sabatier L. Telomere shortening: a new prognostic factor for cardiovascular disease post-radiation exposure. Radiat Prot Dosimetry 2015; 164:134-137. [PMID: 25274533 DOI: 10.1093/rpd/ncu296] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Telomere length has been proposed as a marker of mitotic cell age and as a general index of human organism aging. Telomere shortening in peripheral blood lymphocytes has been linked to cardiovascular-related morbidity and mortality. The authors investigated the potential correlation of conventional risk factors, radiation dose and telomere shortening with the development of coronary artery disease (CAD) following radiation therapy in a large cohort of Hodgkin lymphoma (HL) patients. Multivariate analysis demonstrated that hypertension and telomere length were the only independent risk factors. This is the first study in a large cohort of patients that demonstrates significant telomere shortening in patients treated by radiation therapy who developed cardiovascular disease. Telomere length appears to be an independent prognostic factor that could help determine patients at high risk of developing CAD after exposure in order to implement early detection and prevention.
Collapse
Affiliation(s)
- R M'kacher
- Laboratory of Radiobiology and Oncology, CEA, DSV/iRCM, Fontenay-aux-Roses 92265, France Laboratory of Radiation Sensitivity and Radio-carcinogenesis INSERM 1030, Institut Gustave Roussy, Villejuif 94 804, France
| | - T Girinsky
- Department of Radiation Oncology, Institut Gustave Roussy, Villejuif 94 804, France
| | - B Colicchio
- Laboratoire MIPS - Groupe TIIM3D, Université de Haute-Alsace, Mulhouse Cedex F-68093, France
| | - M Ricoul
- Laboratory of Radiobiology and Oncology, CEA, DSV/iRCM, Fontenay-aux-Roses 92265, France
| | - A Dieterlen
- Laboratoire MIPS - Groupe TIIM3D, Université de Haute-Alsace, Mulhouse Cedex F-68093, France
| | - E Jeandidier
- Department of genetics, CHU, Mulhouse Cedex 68093, France
| | - L Heidingsfelder
- MetaSystems GmbH, Robert-Bosch-Str. 6, Altlussheim D-68804, Germany
| | - C Cuceu
- Laboratory of Radiobiology and Oncology, CEA, DSV/iRCM, Fontenay-aux-Roses 92265, France
| | - G Shim
- Laboratory of Radiobiology and Oncology, CEA, DSV/iRCM, Fontenay-aux-Roses 92265, France
| | - M Frenzel
- Laboratory of Radiobiology and Oncology, CEA, DSV/iRCM, Fontenay-aux-Roses 92265, France Laboratory of Radiation Sensitivity and Radio-carcinogenesis INSERM 1030, Institut Gustave Roussy, Villejuif 94 804, France Department of Radiation Oncology, Institut Gustave Roussy, Villejuif 94 804, France Laboratoire MIPS - Groupe TIIM3D, Université de Haute-Alsace, Mulhouse Cedex F-68093, France Department of genetics, CHU, Mulhouse Cedex 68093, France MetaSystems GmbH, Robert-Bosch-Str. 6, Altlussheim D-68804, Germany Biostatistics and Epidemiology Unit, Institut Gustave Roussy, Villejuif 94 804, France Department of Radiology, Marie Lannelongue, Chatenay-Malabry 92019, France Department of hematology, Institut Gustave Roussy, Villejuif 94 804, France
| | - A Lenain
- Laboratory of Radiobiology and Oncology, CEA, DSV/iRCM, Fontenay-aux-Roses 92265, France
| | - L Morat
- Laboratory of Radiobiology and Oncology, CEA, DSV/iRCM, Fontenay-aux-Roses 92265, France
| | - J Bourhis
- Laboratory of Radiation Sensitivity and Radio-carcinogenesis INSERM 1030, Institut Gustave Roussy, Villejuif 94 804, France Department of Radiation Oncology, Institut Gustave Roussy, Villejuif 94 804, France Laboratoire MIPS - Groupe TIIM3D, Université de Haute-Alsace, Mulhouse Cedex F-68093, France Department of genetics, CHU, Mulhouse Cedex 68093, France
| | - W M Hempel
- Laboratory of Radiobiology and Oncology, CEA, DSV/iRCM, Fontenay-aux-Roses 92265, France
| | - S Koscielny
- Biostatistics and Epidemiology Unit, Institut Gustave Roussy, Villejuif 94 804, France
| | - J F Paul
- Department of Radiology, Marie Lannelongue, Chatenay-Malabry 92019, France
| | - P Carde
- Department of hematology, Institut Gustave Roussy, Villejuif 94 804, France
| | - L Sabatier
- Laboratory of Radiobiology and Oncology, CEA, DSV/iRCM, Fontenay-aux-Roses 92265, France
| |
Collapse
|
9
|
Gosselin K, Martien S, Pourtier A, Vercamer C, Ostoich P, Morat L, Sabatier L, Duprez L, T'kint de Roodenbeke C, Gilson E, Malaquin N, Wernert N, Slijepcevic P, Ashtari M, Chelli F, Deruy E, Vandenbunder B, De Launoit Y, Abbadie C. Senescence-associated oxidative DNA damage promotes the generation of neoplastic cells. Cancer Res 2009; 69:7917-25. [PMID: 19826058 DOI: 10.1158/0008-5472.can-08-2510] [Citation(s) in RCA: 82] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Studies on human fibroblasts have led to viewing senescence as a barrier against tumorigenesis. Using keratinocytes, we show here that partially transformed and tumorigenic cells systematically and spontaneously emerge from senescent cultures. We show that these emerging cells are generated from senescent cells, which are still competent for replication, by an unusual budding-mitosis mechanism. We further present data implicating reactive oxygen species that accumulate during senescence as a potential mutagenic motor of this post-senescence emergence. We conclude that senescence and its associated oxidative stress could be a tumor-promoting state for epithelial cells, potentially explaining why the incidence of carcinogenesis dramatically increases with advanced age.
Collapse
Affiliation(s)
- Karo Gosselin
- Université Lille Nord de France, CNRS, UMR8161, UDSL, Institut Pasteur de Lille, Lille, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Salin H, Ricoul M, Morat L, Sabatier L. Increased genomic alteration complexity and telomere shortening in B-CLL cells resistant to radiation-induced apoptosis. Cytogenet Genome Res 2009; 122:343-9. [PMID: 19188704 DOI: 10.1159/000167821] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/25/2008] [Indexed: 12/12/2022] Open
Abstract
B-cell chronic lymphocytic leukemia (B-CLL) results in an accumulation of mature CD5(+)/CD23(+) B cells due to an uncharacterized defect in apoptotic cell death. B-CLL is not characterized by a unique recurrent genomic alteration but rather by genomic instability giving rise frequently to several chromosomal aberrations. Besides we reported that approximately 15% of B-CLL patients present malignant B-cells resistant to irradiation-induced apoptosis, contrary to approximately 85% of patients and normal human lymphocytes. Telomere length shortening is observed in radioresistant B-CLL cells. Using fluorescence in situ hybridization (FISH) and multicolour FISH, we tested whether specific chromosomal aberrations might be associated with the radioresistance of a subset of B-CLL cells and whether they are correlated with telomere shortening. In a cohort of 30 B-CLL patients, all of the radioresistant B-CLL cell samples exhibited homozygous or heterozygous deletion of 13q14.3 in contrast to 52% of the radiosensitive samples. In addition to the 13q14.3 deletion, ten out of the 11 radioresistant B-cell samples had another clonal genomic alteration such as trisomy 12, deletion 17p13.1, mutation of the p53 gene or translocations in contrast to only three out of 19 radiosensitive samples. Telomere fusions and non-reciprocal translocations, hallmarks of telomere dysfunction, are not increased in radioresistant B-CLL cells. These findings suggest (i) that the 13q14.3 deletion accompanied by another chromosomal aberration is associated with radioresistance of B-CLL cells and (ii) that telomere shortening is not causative of increased clonal chromosomal aberrations in radioresistant B-CLL cells.
Collapse
Affiliation(s)
- H Salin
- Laboratoire de Radiobiologie et d'Oncologie, CEA, DSV/iRCM, Fontenay-aux-Roses, France
| | | | | | | |
Collapse
|
11
|
Raynaud CM, Jang SJ, Nuciforo P, Lantuejoul S, Brambilla E, Mounier N, Olaussen KA, André F, Morat L, Sabatier L, Soria JC. Telomere shortening is correlated with the DNA damage response and telomeric protein down-regulation in colorectal preneoplastic lesions. Ann Oncol 2008; 19:1875-81. [PMID: 18641004 DOI: 10.1093/annonc/mdn405] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND A relation between telomere attrition in early carcinogenesis and activation of DNA damage response (DDR) has been proposed. We explored telomere length and its link with DDR in colorectal multistep carcinogenesis. PATIENTS AND METHODS We studied normal mucosa, low-grade dysplasia (LGD) and high-grade dysplasia (HGD) and invasive carcinoma (IC) in matched human colon specimens by evaluating p-ataxia telangiectasia mutated (ATM), p-checkpoint kinase 2 (Chk2), c-H2AX, TRF1 and TRF2 expressions by immunohistochemistry. FISH was used to assess telomere length. RESULTS Telomeres shortened significantly from normal (N) to LGD and HGD (P < 0.0001; P = 0.012), then increased in length in IC (P = 0.006). TRF1 and TRF2 expressions were diminished from N to LGD and HGD (P = 0.004, P < 0.0001, ns) and were reexpressed at the invasive stage (P = 0.053 and P = 0.046). Phosphorylated ATM, Chk2 and H2AX appeared already in LGD (respectively, P = 0.001, P = 0.002 and P = 0.02). Their expression decreased from HGD to IC (respectively, P = 0.03, P = 0.02 and P = 0.37). These activating phosphorylations were inversely correlated with telomere length and TRF1/2 expression. CONCLUSION In a model of colon multistep carcinogenesis, our data indicate that telomeric length and protein expression levels are inversely correlated with the activation of the DDR pathway.
Collapse
Affiliation(s)
- C M Raynaud
- Laboratoire de Radiobiologie et Oncologie, CEA, Fontenay-aux-Roses, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Fizazi K, Morat L, Chauveinc L, Prapotnich D, De Crevoisier R, Escudier B, Cathelineau X, Rozet F, Vallancien G, Sabatier L, Soria JC. High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity. Ann Oncol 2007; 18:518-21. [PMID: 17322541 DOI: 10.1093/annonc/mdl419] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Circulating tumor cells (CTCs) cannot be readily detected with currently available methods in the majority of patients with prostate cancer. Telomerase activation, one of the major immortalization events, is found in most cases of prostate cancer. We attempted to develop a method using telomerase activity to isolate CTCs in patients with prostate cancer. PATIENTS AND METHODS Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood using Ficoll-Hypaque. Immunomagnetic beads coated with an epithelial cell-specific antigen antibody (BerEP4) were used to harvest epithelial cells from PBMCs. Telomerase activity was detected in harvested epithelial cells using the telomerase-PCR-enzyme-linked immunosorbent assay method. RESULTS Blood samples from 107 patients with prostate cancer were studied. CTCs were detected in 19 of 24 (79%) patients with advanced prostate cancer. In contrast, CTCs were not detected in blood samples from 22 healthy male volunteers. CTCs were even identified in patients with an undetectable (<0.1 ng/ml) serum prostate-specific antigen (PSA). CTCs were detected in 55 of 70 (79%) patients with localized prostate cancer before radical prostatectomy (n = 30) or brachytherapy (n = 40). CTCs were also detected in 3 of 13 patients (23%) with an undetectable serum PSA measured at least 1 year after radical prostatectomy, which is consistent with the expected relapse rate in this setting. CONCLUSION CTCs can be detected using telomerase activity in a large majority and a wide variety of patients with prostate cancer, including those with localized disease.
Collapse
Affiliation(s)
- K Fizazi
- Department of Medicine, Institut Gustave Roussy, Villejuif, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Grenier J, Soria JC, Mathieu MC, Andre F, Abdelmoula S, Velasco V, Morat L, Besse B, Dunant A, Spielmann M, Delaloge S. Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast. Anticancer Res 2007; 27:547-55. [PMID: 17348440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Abstract
BACKGROUND Pure or metaplastic squamous cell carcinoma (SCC) of the breast is a rare entity with an unclear pathogeny and aggressive clinical behaviour. An attempt was made to characterize its differential immunohistochemical and biological profile. PATIENTS AND METHODS Twenty-seven cases of SCC (pure or not) of the breast were matched with 27 ductal invasive carcinomas (IDC) for age, tumour size, nodal involvement and year of diagnosis. The expression levels of oestrogen receptor (ER), progesterone receptor (PR), Ki-67, epidermal growth factor receptor (EGFR), HER2, Cyclin Bl, hTERT, cytokeratins (CK) 5/6 and p63 were determined immunohistochemically in both cohorts. The presence of the human papilloma virus (HPV) genome was investigated by polymerase chain reaction (PCR). RESULTS Pure and metaplastic SCC displayed common profiles typifying a basal origin: they never expressed ER or PR, were HER2-negative in 93% of cases, exhibited positivity for CK5/6 or EGF-R in 75% and 85%, and for p63 in 70% of cases and were highly proliferative. These profiles were markedly different from those of matched controls (p<0.001 for five markers) except for HER2 and hTERT. The HPVgenome was detected in 2 out of 14 cases (14%) of SCC. CONCLUSION The expression profile of SCC of the breast was markedly different from that of IDC. A typical "basal-like" phenotype was displayed that may explain part of their behaviour and justify specific therapeutic approaches. HPV infection was not a leading oncogenic event in SCC of the breast.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Alphapapillomavirus/genetics
- Biomarkers, Tumor/analysis
- Breast Neoplasms/metabolism
- Breast Neoplasms/pathology
- Breast Neoplasms/virology
- Carcinoma, Ductal, Breast/metabolism
- Carcinoma, Ductal, Breast/pathology
- Carcinoma, Ductal, Breast/virology
- Carcinoma, Squamous Cell/metabolism
- Carcinoma, Squamous Cell/pathology
- Carcinoma, Squamous Cell/virology
- Cohort Studies
- DNA-Binding Proteins/analysis
- ErbB Receptors/analysis
- Female
- Humans
- Immunohistochemistry
- Keratin-5/analysis
- Keratin-6/analysis
- Ki-67 Antigen/analysis
- Middle Aged
- Papillomavirus Infections/metabolism
- Papillomavirus Infections/pathology
- Papillomavirus Infections/virology
- Polymerase Chain Reaction
- Receptors, Estrogen/analysis
- Receptors, Progesterone/analysis
- Survival Analysis
- Trans-Activators/analysis
- Transcription Factors
- Tumor Suppressor Proteins/analysis
Collapse
Affiliation(s)
- Julien Grenier
- Department of Medical Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Dutu T, Michiels S, Fouret P, Penault-Llorca F, Validire P, Benhamou S, Taranchon E, Morat L, Grunenwald D, Le Chevalier T, Sabatier L, Soria JC. Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers. Ann Oncol 2005; 16:1906-14. [PMID: 16219624 DOI: 10.1093/annonc/mdi408] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Non-small-cell lung cancer arising in never-smokers is usually of adenocarcinoma subtype. The oncogenic pathway of such tumors is poorly understood. To better define the biological characteristics of these tumors, we have compared the expression of a panel of epidermal growth factor receptor (EGFR)-related biomarkers in lung adenocarcinomas from smokers versus those in never-smokers. PATIENTS AND METHODS Using immunohistochemical analysis, we retrospectively analyzed EGFR, pAKT, PTEN, Ki-67, p27 and hTERT expression in specimens from 190 patients with completely resected lung adenocarcinomas (43 never-smokers and 147 smokers). These analyses were performed on tissue microarrays. RESULTS EGFR expression was higher in tumors from smokers (P < 0.01), while pAKT was overexpressed mainly in tumors from never-smokers (P = 0.01). As expected, the tumors from smokers presented a higher expression of Ki-67 and a more frequent loss of expression of p27 (P < 0.01). In a multivariate model, two biological factors (p27 and Ki-67) and two clinical factors (age and sex) showed independent significant correlation with never-smoking status. CONCLUSIONS Lung adenocarcinomas in never-smokers have a very distinct immunohistochemical expression profile of EGFR-related biomarkers as compared with lung adenocarcinomas in smokers. High levels of EGFR and Ki-67 are observed in smokers, while never-smokers are characterized by high levels of pAKT and p27.
Collapse
Affiliation(s)
- T Dutu
- Department of Medicine, Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Dômont J, Pawlik TM, Boige V, Rose M, Weber JC, Hoff PM, Brown TD, Zorzi D, Morat L, Pignon JP, Rashid A, Jaeck D, Sabatier L, Elias D, Tursz T, Soria JC, Vauthey JN. Catalytic Subunit of Human Telomerase Reverse Transcriptase Is an Independent Predictor of Survival in Patients Undergoing Curative Resection of Hepatic Colorectal Metastases: A Multicenter Analysis. J Clin Oncol 2005; 23:3086-93. [PMID: 15860868 DOI: 10.1200/jco.2005.06.944] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Purpose To determine the role of the catalytic subunit of human telomerase reverse transcriptase (hTERT) in predicting survival after resection of hepatic colorectal metastases (CRM). Patients and Methods Two hundred one patients who underwent curative resection of hepatic CRM between 1990 and 2000 were identified from a multicenter database. The CRM were analyzed for hTERT nucleolar expression by standard immunohistochemical techniques. hTERT expression and known clinicopathologic factors of survival were examined. Results With a median follow-up of 80 months, 152 patients (75.6%) had died; the 5-year overall survival was 30.7%. On univariate analysis, number of metastases greater than two (P = .0005), extrahepatic disease (P = .0054), disease-free interval less than 12 months (P = .006), carcinoembryonic antigen level greater than 200 ng/mL (P = .0071), and positive hTERT nucleolar staining (P < .0001) were associated with decreased survival. On multivariate analysis, three factors independently predicted survival: number of metastases (relative risk [RR] = 1.74; P = .0011); disease-free interval (RR = 1.70; P = .0035); and positive hTERT nucleolar staining (RR = 2.03; P < .0001). Patients with none or one of these factors had a 5-year survival rate of 48%, whereas those with two or three of these factors had a 5-year survival of 15% (P < .0001). Conclusion hTERT nucleolar expression is associated with worse survival after resection of hepatic CRM. hTERT expression in conjunction with number of hepatic metastases and disease-free interval may permit more accurate prediction of survival after resection of hepatic CRM.
Collapse
Affiliation(s)
- Julien Dômont
- Institut Gustave Roussy, Division of Cancer Médecine, 39 Rue Camille Desmoulins, 94805 Villejuif, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Lantuejoul S, Soria JC, Morat L, Lorimier P, Moro-Sibilot D, Sabatier L, Brambilla C, Brambilla E. Telomere Shortening and Telomerase Reverse Transcriptase Expression in Preinvasive Bronchial Lesions. Clin Cancer Res 2005; 11:2074-82. [PMID: 15756034 DOI: 10.1158/1078-0432.ccr-04-1376] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE Telomerase, a ribonucleoprotein complex whose activity is related to the expression of its catalytic subunit human telomerase reverse transcriptase (hTERT), restores telomere length in tumor cells and enables immortality after p53/Rb inactivation has been achieved. To determine the timing of hTERT derepression during bronchial carcinogenesis and its relationship with telomere shortening and the p53/Rb pathway alterations, we did an immunohistochemical and in situ hybridization study in preinvasive and invasive bronchial lesions. EXPERIMENTAL DESIGN hTERT, P53, P16, cyclin D1, Bax-to-Bcl2 ratio, and Ki67 immunostainings were done in 106 preneoplastic lesions and in paired lung carcinoma and normal bronchial mucosae. Concomitantly, hTERT mRNA levels and qualitative telomere shortening were assessed by in situ hybridization and fluorescence in situ hybridization, respectively, in a subset of preneoplastic and neoplastic lesions. RESULTS Telomerase was increasingly expressed from normal epithelium to squamous metaplasia, dysplasia, and carcinoma in situ, and decreased in invasive carcinoma (P < 0.0001), with a direct correlation between protein and mRNA levels of expression (P < 0.0001). hTERT expression was directly correlated with P53, Ki67, and Bcl2-to-Bax ratio, suggesting a coupling between telomerase reactivation, proliferation, and resistance to apoptosis. Telomere signals significantly decreased as early as squamous metaplasia and progressively increased over the spectrum of preneoplastic lesions. CONCLUSIONS Telomere shortening represents an early genetic abnormality in bronchial carcinogenesis, preceding telomerase expression and p53/Rb inactivation, which predominate in high-grade preinvasive lesions.
Collapse
Affiliation(s)
- Sylvie Lantuejoul
- Department of Pathology, Centre Hospitalier Universitaire Albert Michallon, 38043 Grenoble Cedex 9, France
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Erman M, Grunenwald D, Penault-Llorca F, Grenier J, Besse B, Validire P, Morat L, Girard P, Le Chevalier T, Sabatier L, Soria JC. Epidermal growth factor receptor, HER-2/neu and related pathways in lung adenocarcinomas with bronchioloalveolar features. Lung Cancer 2005; 47:315-23. [PMID: 15713515 DOI: 10.1016/j.lungcan.2004.08.015] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2004] [Revised: 07/01/2004] [Accepted: 08/11/2004] [Indexed: 01/09/2023]
Abstract
Lung adenocarcinomas with bronchioalveolar features (ABAF), formerly called bronchioloalveolar cancers (BAC), constitute a distinct clinical, radiological and pathological entity among lung malignancies. Epidermal growth factor receptor (EGFR) and to a less extent, HER-2/neu, are known to be overexpressed in non-small lung cancers, but their exact status in ABAF is not well-documented. Stimulation of these two receptors results in the initiation of two major cascades, namely phosphatidylinositol 3-kinase (PI-3K) and Ras-dependent pathways. We have therefore studied the expressions of EGFR, HER-2/neu as well as phosphorylated AKT (pAKT) and phosphorylated extracellular-signal regulated kinase (ERK), which are key molecules in these two pathways, in 15 ABAF patients. EGFR was found to be overexpressed in 9 of 15 patients (60%). HER-2/neu overexpression was detected in 6 of the 14 tumors tested (43%). pAKT and pERK were both found to be positive in 13 of 15 patients (87%). Six of the seven tumors with mucinous pattern were negative for EGFR, while all of the other eight cases were positive (P=0.001). Mucinous tumors were also less likely than non-mucinous tumors to overexpress HER-2/neu (17% versus 63%, respectively). These findings suggest that ABAF, particularly those with non-mucinous histology, commonly harbors EGFR and HER-2/neu overexpression. PI-3K and Ras-dependant pathways that lie downstream are generally activated, even in the absence of EGFR and/or HER-2/neu overexpression. ABAF may be a particularly promising candidate for EGFR-targeted strategies and this possibility merits extensive evaluation in clinical trials.
Collapse
Affiliation(s)
- Mustafa Erman
- Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Erman M, Planchard D, Spano JP, Lassalle M, Morat L, Caliandro R, Validire P, Grunenwald D, Ruffie P, Soria JC. Nuclear expression of CXCR4 is an independent prognostic factor for overall and progression-free survival in malignant pleural mesothelioma. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Erman
- Institut Gustave-Roussy, Villejuif, France; Hopital Pitie Salpetriere, Paris, France; Commissariat a l'Energie Atomique, Fontenay-aux-Roses, France; Institut Mutualiste Montsouris, Paris, France
| | - D. Planchard
- Institut Gustave-Roussy, Villejuif, France; Hopital Pitie Salpetriere, Paris, France; Commissariat a l'Energie Atomique, Fontenay-aux-Roses, France; Institut Mutualiste Montsouris, Paris, France
| | - J.-P. Spano
- Institut Gustave-Roussy, Villejuif, France; Hopital Pitie Salpetriere, Paris, France; Commissariat a l'Energie Atomique, Fontenay-aux-Roses, France; Institut Mutualiste Montsouris, Paris, France
| | - M. Lassalle
- Institut Gustave-Roussy, Villejuif, France; Hopital Pitie Salpetriere, Paris, France; Commissariat a l'Energie Atomique, Fontenay-aux-Roses, France; Institut Mutualiste Montsouris, Paris, France
| | - L. Morat
- Institut Gustave-Roussy, Villejuif, France; Hopital Pitie Salpetriere, Paris, France; Commissariat a l'Energie Atomique, Fontenay-aux-Roses, France; Institut Mutualiste Montsouris, Paris, France
| | - R. Caliandro
- Institut Gustave-Roussy, Villejuif, France; Hopital Pitie Salpetriere, Paris, France; Commissariat a l'Energie Atomique, Fontenay-aux-Roses, France; Institut Mutualiste Montsouris, Paris, France
| | - P. Validire
- Institut Gustave-Roussy, Villejuif, France; Hopital Pitie Salpetriere, Paris, France; Commissariat a l'Energie Atomique, Fontenay-aux-Roses, France; Institut Mutualiste Montsouris, Paris, France
| | - D. Grunenwald
- Institut Gustave-Roussy, Villejuif, France; Hopital Pitie Salpetriere, Paris, France; Commissariat a l'Energie Atomique, Fontenay-aux-Roses, France; Institut Mutualiste Montsouris, Paris, France
| | - P. Ruffie
- Institut Gustave-Roussy, Villejuif, France; Hopital Pitie Salpetriere, Paris, France; Commissariat a l'Energie Atomique, Fontenay-aux-Roses, France; Institut Mutualiste Montsouris, Paris, France
| | - J.-C. Soria
- Institut Gustave-Roussy, Villejuif, France; Hopital Pitie Salpetriere, Paris, France; Commissariat a l'Energie Atomique, Fontenay-aux-Roses, France; Institut Mutualiste Montsouris, Paris, France
| |
Collapse
|
19
|
Smith DL, Soria JC, Morat L, Yang Q, Sabatier L, Liu DD, Nemr RA, Rashid A, Vauthey JN. Human telomerase reverse transcriptase (hTERT) and Ki-67 are better predictors of survival than established clinical indicators in patients undergoing curative hepatic resection for colorectal metastases. Ann Surg Oncol 2004; 11:45-51. [PMID: 14699033 DOI: 10.1007/bf02524345] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
BACKGROUND We evaluated hTERT and Ki-67 expression in patients who underwent curative resection of hepatic colorectal metastases to determine if these markers of cell proliferation correlated better with survival than an established scoring system that is based on clinical predictors. METHODS Patients operated on between 1993 and 1997 whose survival time was known were analyzed. For each patient, the clinical prognostic score was derived on the basis of primary node status, disease-free interval, number of hepatic tumors, largest tumor, and carcinoembryonic antigen level, and tumor specimens were analyzed for Ki-67 and hTERT with use of standard immunohistochemical techniques. The immunohistochemical analysis was blinded to all patient characteristics. RESULTS The study included 66 patients. Twenty-six survived less than 2 years after surgery, 19 survived 2-5 years, and 21 survived more than 5 years. Ki-67 positivity and hTERT positivity (labeling indexes greater than or equal to 50%) were observed in 24 patients and 23 patients, respectively. The clinical score did not predict survival, although there was a weak trend toward a lower score in patients with better survival. Both Ki-67 (P =.04) and hTERT (P =.0001) correlated better with survival than did the clinical score. CONCLUSIONS In patients undergoing curative resection of hepatic colorectal metastases, hTERT and Ki-67 are better predictors of survival than is a score based on clinical features.
Collapse
Affiliation(s)
- David L Smith
- Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Lantuejoul S, Soria JC, Moro-Sibilot D, Morat L, Veyrenc S, Lorimier P, Brichon PY, Sabatier L, Brambilla C, Brambilla E. Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours. Br J Cancer 2004; 90:1222-9. [PMID: 15026805 PMCID: PMC2410220 DOI: 10.1038/sj.bjc.6601643] [Citation(s) in RCA: 78] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023] Open
Abstract
Human telomerase reverse transcriptase is a ribonucleoprotein that synthesises telomeric sequences, which decrease at each cell division. In cancer cells, its activity is linked to telomere maintenance leading to unlimited cellular proliferation and immortality. To evaluate the prognostic value of the catalytic subunit telomerase reverse transcriptase (hTERT), we analysed its expression by immunohistochemistry in 122 formalin-fixed lung tumours including 42 squamous cell carcinoma (SCC), 43 adenocarcinoma (ADC), 19 basaloid carcinoma (BC) and 18 small-cell lung carcinoma (SCLC) in comparison with detection of hTERT mRNA by in situ hybridisation and relative telomerase activity by TRAP assay in a subset of tumours. We observed a high concordance between hTERT protein expression and detection of hTERT mRNA and telomerase activity. Telomerase expression varied according to histology (P=0.0002) being significantly lower in ADC than in SCC, BC and SCLC (P<0.0001). Adenocarcinoma and SCC exhibited either a nuclear or a nucleolar staining in contrast with a diffuse nuclear staining observed in most BC and all SCLC (P=0.01). In stage I NSCLC telomerase expression was lower than in other stages (P=0.04), and a nucleolar staining was correlated with a short survival (P=0.03). We concluded that telomerase expression and pattern are distinctive among histopathological classes of lung cancer and convey prognostic influence.
Collapse
Affiliation(s)
- S Lantuejoul
- Service de Pathologie Cellulaire, Institut A Bonniot, CHU Michallon Grenoble, France
- Lung Cancer Research Group INSERM U 578, Institut A Bonniot, CHU Michallon Grenoble, France
| | - J C Soria
- Laboratoire de Radiobiologie et Oncologie DSV-DRR CEA Fontenay aux Roses, France
| | - D Moro-Sibilot
- Lung Cancer Research Group INSERM U 578, Institut A Bonniot, CHU Michallon Grenoble, France
| | - L Morat
- Laboratoire de Radiobiologie et Oncologie DSV-DRR CEA Fontenay aux Roses, France
| | - S Veyrenc
- Service de Pathologie Cellulaire, Institut A Bonniot, CHU Michallon Grenoble, France
- Lung Cancer Research Group INSERM U 578, Institut A Bonniot, CHU Michallon Grenoble, France
| | - P Lorimier
- Service de Pathologie Cellulaire, Institut A Bonniot, CHU Michallon Grenoble, France
- Lung Cancer Research Group INSERM U 578, Institut A Bonniot, CHU Michallon Grenoble, France
| | - P Y Brichon
- Lung Cancer Research Group INSERM U 578, Institut A Bonniot, CHU Michallon Grenoble, France
| | - L Sabatier
- Laboratoire de Radiobiologie et Oncologie DSV-DRR CEA Fontenay aux Roses, France
| | - C Brambilla
- Lung Cancer Research Group INSERM U 578, Institut A Bonniot, CHU Michallon Grenoble, France
| | - E Brambilla
- Service de Pathologie Cellulaire, Institut A Bonniot, CHU Michallon Grenoble, France
- Lung Cancer Research Group INSERM U 578, Institut A Bonniot, CHU Michallon Grenoble, France
- Service de Pathologie Cellulaire, CHU A. Michallon, BP 217 Cedex 9, 38043 Grenoble, France. E-mail:
| |
Collapse
|
21
|
Spano JP, Andre F, Morat L, Sabatier L, Besse B, Combadiere C, Deterre P, Martin A, Azorin J, Valeyre D, Khayat D, Le Chevalier T, Soria JC. Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol 2004; 15:613-7. [PMID: 15033669 DOI: 10.1093/annonc/mdh136] [Citation(s) in RCA: 179] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND The expression of CXCR4 has been implicated in metastatic dissemination in different models of breast cancer and melanoma. In the present study, we evaluated CXCR4 expression in non-small-cell lung cancer (NSCLC) and the relationship between CXCR4 expression and the prognosis of stage I disease. PATIENTS AND METHODS Using immunohistochemical analysis, we retrospectively analyzed CXCR4 expression in specimens from 61 patients with completely resected pathologically confirmed stage I NSCLC for whom clinical follow-up data were available. RESULTS In the present study, we have shown that: CXCR4 is expressed by tumor cells in stage I NSCLC; CXCR4 is located in the nucleus and/or in the cytoplasm of tumor cells; strong nuclear staining was observed in 17 cases (29.8%); patients whose tumors had CXCR4-positive nuclear staining had a significantly longer duration of survival than patients whose tumors had no nuclear expression (P = 0.039, log-rank test). Interestingly, the 5-year metastasis rates were 23.5% and 34.1% in patients with CXCR4-positive and CXCR4-negative nuclear expression, respectively (P = 0.2). CONCLUSION Strong CXCR4-positive nuclear staining was associated with a significantly better outcome in early-stage NSCLC. The mechanisms underlying this clinically and biologically important finding need to be further explored.
Collapse
Affiliation(s)
- J-P Spano
- SOMPS, Pitié Salpetrière Hospital, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Ady N, Morat L, Fizazi K, Soria JC, Mathieu MC, Prapotnich D, Sabatier L, Chauveinc L. Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients. Br J Cancer 2004; 90:443-8. [PMID: 14735191 PMCID: PMC2409539 DOI: 10.1038/sj.bjc.6601532] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
HER-2/neu may play a role in prostate carcinogenesis. The aim of this study was to use the expression of HER-2/neu as a molecular marker for the detection of circulating tumour cells (CTCs) in the blood of patients with prostate cancer (PC). Blood samples were collected from 42 patients with PC and nine healthy volunteers. Immunomagnetic beads were used to harvest epithelial cells from peripheral blood mononuclear cells. Total RNA was extracted and reverse transcribed before analysis by real-time PCR with HER-2/neu-specific primers. CTCs were HER-2/neu positive in six out of 11 (54%) patients with metastatic disease and in three out of 31 (9.6%) patients with localised PC (P=0.004). In blood samples from nine healthy volunteers, we detected no expression of HER-2/neu. The present method appears to be minimally invasive, highly sensitive and a specific approach for detecting CTCs in PC. Furthermore, it may help better target HER-2/neu in advanced PC.
Collapse
Affiliation(s)
- N Ady
- CEA, Laboratoire de Radiobiologie et Oncologie, DRR/DSV, 92265 Fontenay-aux-Roses, France
| | - L Morat
- CEA, Laboratoire de Radiobiologie et Oncologie, DRR/DSV, 92265 Fontenay-aux-Roses, France
| | - K Fizazi
- Département de Médecine, Institut Gustave Roussy, 94805 Villejuif, France
| | - J-C Soria
- CEA, Laboratoire de Radiobiologie et Oncologie, DRR/DSV, 92265 Fontenay-aux-Roses, France
- Département de Médecine, Institut Gustave Roussy, 94805 Villejuif, France
| | - M-C Mathieu
- Département d'Anatomopathologie, Institut Gustave Roussy, 94805 Villejuif, France
| | - D Prapotnich
- Service d'Urologie, Institut Mutualiste Montsouris, 75014 Paris, France
| | - L Sabatier
- CEA, Laboratoire de Radiobiologie et Oncologie, DRR/DSV, 92265 Fontenay-aux-Roses, France
- CEA, Laboratoire de Radiobiologie et Oncologie, DRR/DSV, 92265 Fontenay-aux-Roses, France. E-mail:
| | - L Chauveinc
- CEA, Laboratoire de Radiobiologie et Oncologie, DRR/DSV, 92265 Fontenay-aux-Roses, France
- Département de Radiothérapie, Institut Curie, 75005 Paris, France
| |
Collapse
|
23
|
Masmoudi A, Fayette J, Slimane K, Temam S, Morat L, Soria JC. [Epidermal growth factor receptor and chemoprevention of epithelial tumor: rationale and development methods]. Bull Cancer 2003; 90 Spec No:S251-6. [PMID: 14763148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/28/2023]
Abstract
Among the many pathways dysregulated during the carcinogenic process, REGF seems to be one of the most promising pathways to target in order to achieve chemopreventive and anticancer effects. Indeed, chemoprevention, the use of natural or synthetic compounds in order to reverse, suppress or prevent the carcinogenic process, aims at the cellular level at regulating the growth and sensitivity to apoptosis of premalignant and malignant clones. REGF activation leads to uncontrolled cellular proliferation, resistance to apoptosis, angiogenesis and invasion. Furthermore, REGF is frequently overexpressed in many epithelial tumors. This review will focus on the rationale and the ongoing research areas related to chemopreventive approaches targeting REGF.
Collapse
Affiliation(s)
- Amine Masmoudi
- Département de médecine, Institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94805 Villejuif
| | | | | | | | | | | |
Collapse
|
24
|
Olaussen KA, Soria JC, Morat L, Martin A, Sabatier L, Morere JF, Khayat D, Spano JP. Loss of PTEN expression is not uncommon, but lacks prognostic value in stage I NSCLC. Anticancer Res 2003; 23:4885-90. [PMID: 14981940] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
The PTEN gene is a tumor-suppressor gene that is inactivated in several types of human tumors. The loss of PTEN expression has been supported as a prognostic marker. Using immunohistochemical analysis, we retrospectively analyzed PTEN expression in specimens from 53 patients with completely resected stage I non-small cell lung cancer (NSCLC) for whom clinical follow-up data were available. Seven of the 53 specimens showed a total lack of staining for PTEN. No statistically significant relationship could be found between PTEN expression and clinicopathological parameters. Although genetic alterations of the PTEN gene are rare in NSCLC, loss of PTEN protein is not an uncommon event in early-stage NSCLC (13.2%). Here, we also report that the level of PTEN protein expression is not an independent prognostic marker in early-stage NSCLC.
Collapse
|
25
|
Grunenwald DH, Validire P, Galetta D, Besse B, Morat L, Wislez M, Le Chevalier T, Soria JC. O-258 Bronchioloalveolar carcinoma and the EGFR pathway. Lung Cancer 2003. [DOI: 10.1016/s0169-5002(03)91916-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
26
|
Soria JC, Morat L, Durdux C, Housset M, Cortez A, Blaise R, Sabatier L. The molecular detection of circulating tumor cells in bladder cancer using telomerase activity. J Urol 2002; 167:352-6. [PMID: 11743355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
PURPOSE The detection of circulating tumor cells and micrometastases may have important prognostic and therapeutic implications. We investigated telomerase activity as a molecular marker for detecting bladder carcinoma cells in blood. MATERIALS AND METHODS Peripheral blood mononuclear cells were isolated from whole blood using Ficoll/Hypaque. Immuno-magnetic beads labeled with an epithelial specific antibody were used to harvest epithelial cells from peripheral blood mononuclear cells. Telomerase activity was detected in this select population using the telomerase-polymerase chain reaction-enzyme-linked immunosorbent assay test based on the telomerase repeat amplification protocol method. The clinical applicability of this technique was explored by evaluating 30 patients with muscle invasive or metastatic bladder carcinoma and 17 healthy volunteers. RESULTS Telomerase expression was detected in 27 of the 30 patients (90%) with high grade, muscle invasive or metastatic bladder cancer but in none of the 17 healthy controls. CONCLUSIONS This test is a minimally invasive and specific approach for detecting circulating epithelial cells in patients with bladder cancer. This method may have great value for monitoring cancer progression.
Collapse
Affiliation(s)
- Jean-Charles Soria
- Laboratoire de Radiobiologie et Oncologie, DRR/DSV, CEA, Fontenay-aux-Roses, Tenon Hospital, AP-HP, Paris, France
| | | | | | | | | | | | | |
Collapse
|
27
|
Soria JC, Morat L, Commo F, Dabit D, Perie S, Sabatier L, Fouret P. Telomerase activation cooperates with inactivation of p16 in early head and neck tumorigenesis. Br J Cancer 2001; 84:504-11. [PMID: 11207046 PMCID: PMC2363771 DOI: 10.1054/bjoc.2000.1647] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Alteration of the p16/pRb pathway may cooperate with telomerase activation during cellular immortalization and tumour progression. We studied p16 expression status by immunohistochemistry and telomerase activity using the TRAP assay in 21 premalignant lesions of the head and neck epithelium as well as 27 squamous-cell carcinomas. We also examined expression of other components of the pathway (cyclin D1 and pRb) as well as presence of human papillomavirus genomes which can target these molecules. 4 of 9 mild dysplastic lesions (44%), 8 of 12 moderate/severe dysplastic lesions (67%), and 25 of 27 squamous-cell carcinomas (92%) demonstrated high telomerase activity (P = 0.009). There was a parallel increase with severity of lesions for the trend in proportions of cases demonstrating p16 inactivation or cyclin D1 overexpression (P = 0.02 and P = 0.01, respectively). For Ki67, a marker of cell proliferation, this trend was not significant (P = 0.08). Human papillomavirus infection was only found in 4 cases among the 48 samples tested (8.3%). In conclusion, progression of disease is accompanied by a parallel and continuous increase in telomerase activity and alterations in cell cycle regulators (p16, cyclin D1), as proposed by in vitro models.
Collapse
Affiliation(s)
- J C Soria
- Service d'Anatomie Pathologique (Pr. P. CALLARD), Hôpital Tenon, UFR Saint-Antoine, Paris, France
| | | | | | | | | | | | | |
Collapse
|
28
|
Soria JC, Gauthier LR, Raymond E, Granotier C, Morat L, Armand JP, Boussin FD, Sabatier L. Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients. Clin Cancer Res 1999; 5:971-5. [PMID: 10353728] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
The detection of circulating tumor cells and micrometastases may have important therapeutic and prognostic implications. Telomerase is a hallmark of cancer and is absent from normal epithelial cells. The aim of this study was to use telomerase activity as a molecular marker for the detection of cancer cells in blood of patients with breast cancer. Blood samples were collected from 25 women with stage IV breast cancer and 9 healthy volunteers. Peripheral blood mononuclear cells were isolated by using Ficoll/Hypaque. Immunomagnetic beads coated with an epithelial-specific antibody (BerEP4) were used to harvest epithelial cells from peripheral blood mononuclear cells. Telomerase activity was detected in harvested epithelial cells (HECs) using two different telomerase-PCR-ELISA methods. HECs from blood samples of 21 of 25 (84%) patients with breast cancer were telomerase positive. Telomerase activity was undetectable in HECs from the nine healthy volunteers, demonstrating the specificity of the association between telomerase activity in HECs and stage IV breast cancer. Thus, determination of telomerase activity in HECs appears to be a sensitive, specific, and noninvasive approach for detecting circulating epithelial cancer cells in patients with metastatic breast cancer. This method could be of great value in monitoring the cancer cell proliferation during chemotherapy. This study should be now extended to patients with early-stage breast cancer to investigate the role of telomerase expression by HECs and to evaluate its prognostic value.
Collapse
Affiliation(s)
- J C Soria
- Laboratoire de Radiobiologie et Oncologie, DRR/DSV, CEA, Fontenay-aux-Roses, France
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Gachot B, Tauc M, Wanstok F, Morat L, Poujeol P. Zinc transport and metallothionein induction in primary cultures of rabbit kidney proximal cells. Biochim Biophys Acta 1994; 1191:291-8. [PMID: 8172914 DOI: 10.1016/0005-2736(94)90179-1] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Primary cultures of isolated rabbit renal proximal cells were grown on collagen-coated permeable supports. The confluent epithelia were polarized, making possible the measurement of uptakes and effluxes across the apical and the basolateral membranes. Uptakes of 65Zn were assessed under initial rate conditions, after 0.5 min incubation. The kinetic parameters of apical uptake were a Jmax of 25.1 +/- 5.3 pmol min-1 (micrograms DNA)-1, a Km of 43.3 +/- 7.3 microM and an unsaturable constant of 0.105 +/- 0.029 (n = 7) at 37 degrees C. Cadmium competitively inhibited the zinc uptake, with a Ki value of 24.5 +/- 7.3 microM. Basolateral uptake was characterized by a high capacity (Jmax = 227.9 +/- 46.6 pmol min-1 (micrograms DNA)-1) and an affinity similar to that of the apical uptake (Km = 35.4 +/- 14.2 microM). Cadmium had no effect on the basolateral zinc uptake. Effluxes across the basolateral face of the epithelium always exceeded those across the apical face. Excess zinc in the culture medium induced the synthesis of metallothionein in the epithelia, as judged by the rate of [35S]cysteine incorporation into a fraction of cytosolic proteins. Metallothionein induction did not appear to modify the kinetic parameters of the apical zinc uptake. These data suggest that separate saturable transport systems are responsible for the apical and basolateral zinc uptakes in proximal renal cells. Induction of metallothionein had no apparent effect on apical zinc uptake in this system.
Collapse
Affiliation(s)
- B Gachot
- Département de Biologie Cellulaire et Moléculaire, Centre d'Etudes de Saclay, Gif sur Yvette, France
| | | | | | | | | |
Collapse
|
30
|
Abstract
The aim of this study was to characterize the mechanisms of zinc transport in proximal cells isolated from rabbit kidney cortex. Uptakes of 65Zn were assessed under initial rate conditions, after 0.5 min of incubation. The kinetic parameters obtained at 20 degrees C were a Km of 15.0 +/- 1.5 microM, a Jmax of 208.0 +/- 8.4 pmol min-1 (mg protein)-1, and an unsaturable constant of 0.259 +/- 0.104 (n = 8). Cadmium competitively inhibited the zinc uptake, with a Ki value of 13.0 +/- 2.8 microM, while zinc competitively inhibited 109Cd uptake by isolated cells. Cysteine and histidine stimulated zinc transport at an amino acid:zinc molar ratio ranging from 1:1 to 8:1. This stimulation was not observed in the absence of a sodium gradient. At a molar ratio greater than 16:1 (i.e. 400 microM cysteine or histidine and 25 microM Zn), there was evidence of inhibition. These data suggest that zinc enters renal proximal cells (a) as a free ion via a saturable carrier-mediated process or an unsaturable pathway and (b) complexed with cysteine or histidine, by means of a sodium/amino acid cotransport mechanism.
Collapse
Affiliation(s)
- B Gachot
- Département de Biologie cellulaire et moléculaire, CEN Saclay, Gif sur Yvette, France
| | | | | | | |
Collapse
|